Novo Nordisk Q3 earnings: Wegovy sales soar 79% year-over-year

Novo Nordisk (NVO) revealed mixed third quarter results, the pharmaceutical giant narrowing its full-year sales growth guidance while posting a 79% year-over-year sales increase for its landmark weight-loss drug Wegovy.